ACTU News
Archived Headlines
- US IPO Week Ahead: July IPO market set to end with a quiet week 07/26/24
- Cancer biotech Actuate Therapeutics further revises terms ahead of $27 million IPO 07/23/24
- US IPO Week Ahead: Flurry of large IPOs set to raise more than $5 billion in 2024’s biggest week so far 07/19/24
- Cancer biotech Actuate Therapeutics slashes share offering by 50% ahead of $25 million IPO 07/19/24
- Cancer biotech Actuate Therapeutics sets terms for $50 million IPO 06/11/24
See more
Renaissance Capital's August IPO Market Update
Amid the typical summer slowdown, the month of August saw 7 small IPOs raise a combined $90 million, most of which were based in Asia. Activity rose slightly from last August, but was below the 10-year historical average by deal count (9 IPOs), and well below...read more
US IPO Weekly Recap: WeRide reschedules while six new filers join the pipeline
This week was another slow week for pricings, with two companies making their public debut, along with three SPACs. WeRide (WRD) was set to break the August drought for large IPOs, but pushed back its expected pricing date to next week. Six...read more
Cancer biotech Actuate Therapeutics prices downsized IPO at $8 low end
Actuate Therapeutics, a Phase 2 biotech developing an inhibitor therapy for difficult to treat cancers, raised $22 million by offering 2.8 million shares at $8, the low end of the range of $8 to $10. The company offered 150,000 shares fewer than anticipated...read more
US IPO Week Ahead: 1 IPO expected in quiet week as summer lull sets in
Just one IPO is currently scheduled to list in the week ahead, although some small issuers may join the calendar during the week. Holdover Actuate Therapeutics (ACTU) is scheduled to raise $27 million at a $182 million market cap. Actuate has...read more